Clarithromycin [clinicaltrials_resource:e776283175ad4d40f8848f672852d163]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT00331643 [clinicaltrials_resource:04e94b8a43da0e6fb95715b99650bb9c]eligibility for clinicaltrials:NCT01835145 [clinicaltrials_resource:22853b78666e9653a2ef02f18dcab961]eligibility for clinicaltrials:NCT00107536 [clinicaltrials_resource:273f28a85c6566d76ff76854cd53b9fb]eligibility for clinicaltrials:NCT00070109 [clinicaltrials_resource:2be59c7deb57fbbf3509352ef6f891c2]eligibility for clinicaltrials:NCT00134069 [clinicaltrials_resource:31c44eb02996a6c0ff1a0b62791f3b16]eligibility for clinicaltrials:NCT00118157 [clinicaltrials_resource:38c27da684633d4e18d079b4d14c3854]eligibility for clinicaltrials:NCT00397787 [clinicaltrials_resource:44f7445b33573724f39d2c3350c2edd2]eligibility for clinicaltrials:NCT00617708 [clinicaltrials_resource:5779b97f6e8f19f4261bc4fbf6ffca8f]eligibility for clinicaltrials:NCT00301756 [clinicaltrials_resource:5be956883f0e12d02fa5f13b3bd89e15]eligibility for clinicaltrials:NCT00410904 [clinicaltrials_resource:740cb91f749a254954ae598a778f0c17]eligibility for clinicaltrials:NCT00378911 [clinicaltrials_resource:90e2573b962fa7b00d8bc3d81c673d4b]eligibility for clinicaltrials:NCT00096499 [clinicaltrials_resource:a07408bbc65c5b2266e419ce0526be68]eligibility for clinicaltrials:NCT00906360 [clinicaltrials_resource:ab102d1f180ab3114d9eef4e4cd8cffd]eligibility for clinicaltrials:NCT00387920 [clinicaltrials_resource:ae648621e7eda92397728786d3a31e65]eligibility for clinicaltrials:NCT02066181 [clinicaltrials_resource:b75bbb3aebffbab9512c0286dff621a7]eligibility for clinicaltrials:NCT00398112 [clinicaltrials_resource:baa879f991df91a619bf63a4eb76ddf8]eligibility for clinicaltrials:NCT00321594 [clinicaltrials_resource:bb6f8a91caf17688756b2aea0fc0a8a3]eligibility for clinicaltrials:NCT00070525 [clinicaltrials_resource:bbc57e24ec459e18f6e64dc2c331a766]eligibility for clinicaltrials:NCT00119236 [clinicaltrials_resource:d8177edb3af609f1c135ac1b3cd473fc]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS [clinicaltrials:NCT00000644]Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis [clinicaltrials:NCT00000794]Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites [clinicaltrials:NCT00000826]The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS [clinicaltrials:NCT00000971]The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients [clinicaltrials:NCT00001023]The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients [clinicaltrials:NCT00001030]Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients [clinicaltrials:NCT00001039]Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS [clinicaltrials:NCT00001047]A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS [clinicaltrials:NCT00001058]A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo [clinicaltrials:NCT00002101]A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients [clinicaltrials:NCT00002140]Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia. [clinicaltrials:NCT00002192]An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4. [clinicaltrials:NCT00002194]The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS [clinicaltrials:NCT00002331]The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients [clinicaltrials:NCT00002336]clinicaltrials:NCT00002682Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma [clinicaltrials:NCT00003151]Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach [clinicaltrials:NCT00003617]Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease [clinicaltrials:NCT00004689]Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma [clinicaltrials:NCT00006219]The CLARICOR Trial: Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease [clinicaltrials:NCT00121550]Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori [clinicaltrials:NCT00149084]Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma [clinicaltrials:NCT00151203]Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation [clinicaltrials:NCT00154440]Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant [clinicaltrials:NCT00182663]Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection [clinicaltrials:NCT00197418]Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-Grade B Cell Lymphoma of MALToma [clinicaltrials:NCT00201422]Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis [clinicaltrials:NCT00205634]Outpatient Registry Trial of Respiratory Tract Infections in Adults [clinicaltrials:NCT00245453]Clarithromycin in Active Crohn's Disease [clinicaltrials:NCT00269386]The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy [clinicaltrials:NCT00281047]Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital [clinicaltrials:NCT00285688]Intravenous Clarithromycin in Septic Syndrome [clinicaltrials:NCT00297674]clinicaltrials:NCT00318708clinicaltrials:NCT00321178Prospective Study of First-Line Antibiotic Therapy for Early-Stage Gastric MALT Lymphoma for Treatment Outcome [clinicaltrials:NCT00327132]clinicaltrials:NCT00336505clinicaltrials:NCT00336544Selection of Antibiotic Resistance by Azithromycin and Clarithromycin in the Oral Flora [clinicaltrials:NCT00354952]Antibiotics for the Treatment of Ulcerative Colitis [clinicaltrials:NCT00355602]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Clarithromycin [clinicaltrials_resource:e776283175ad4d40f8848f672852d163]
Bio2RDF identifier
e776283175ad4d40f8848f672852d163
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e776283175ad4d40f8848f672852d163
identifier
clinicaltrials_resource:e776283175ad4d40f8848f672852d163
title
Clarithromycin
@en
type
label
Clarithromycin [clinicaltrials_resource:e776283175ad4d40f8848f672852d163]
@en